Skip to main content

Table 3 Major clinical and laboratory characteristic of BSLE and control SLE group

From: Clusters of clinical and immunologic features in patients with bullous systemic lupus erythematosus: experience from a single-center cohort study in China

Variable

BSLE group (n = 12)

Single SLE group (n = 48)

P value

Age (years, mean ± SD)

25.9 ± 13.3

27.3 ± 14.4

0.766

Gender (F/M)

2/10

4/44

0.389

Disease duration (months, mean ± SD)

26.5 ± 32.9

46.0 ± 51.2

0.215

Arthritis (n, %)

6 (50.0)

22 (45.8)

0.796

Renal involvement (n, %)

11 (91.7)

25 (52.1)

0.012*

Nephrotic syndrome (n, %)

4 (33.3)

6 (12.5)

0.083

Proteinuria (n, %)

10 (83.3)

23 (47.9)

0.027*

Hematuria (n, %)

9 (75.0)

15 (31.3)

0.006*

Renal insufficiency (n, %)

4 (33.3)

6 (12.5)

0.083

Hemocytopenia (n, %)

10 (83.3)

19 (39.6)

0.007*

Hemolytic anemia (n, %)

4 (33.3)

0 (0.0)

0.000*

Leukopenia (n, %)

8 (66.7)

12 (25.0)

0.006*

Thrombocytopenia (n, %)

2 (16.7)

12 (25.0)

0.542

Myositis (n, %)

0 (0)

3 (6.3)

0.374

Neurological involvement (n, %)

3 (25.0)

9 (18.8)

0.628

Cardiac damage (n, %)

2 (16.7)

17 (35.4)

0.212

Gastrointestinal involvement (n, %)

1 (8.3)

8 (25.0)

0.449

Anti-dsDNA antibody (n, %)

8 (66.7)

23 (47.9)

0.245

Anti-Sm antibody (n, %)

2 (16.7)

7 (14.6)

0.857

Anti-RNP antibody (n, %)

2 (25.0)

14 (29.2)

0.774

Anti-rRNP antibody (n, %)

4 (33.3)

6 (12.5)

0.083

Anti-SSA antibody (n, %)

6 (50.0)

16 (33.3)

0.284

Anti-SSB antibody (n, %)

3 (25.0)

3 (6.3)

0.053

  1. *Denotes P < 0.05